filmov
tv
Does Continuing Beta-Blockers After a Heart Attack Make a Difference? New Study Sheds Lights
Показать описание
#betablockerscontinuation #heartattack #abysstrial
New research presented at ESC Congress 2024 found that stopping beta-blocker treatment after a heart attack doesn’t improve patient outcomes or quality of life compared to continuing the medication.
The open-label, non-inferiority, randomised ABYSS trial, conducted by the ACTION Group, included patients with a prior myocardial Infarction(MI) taking long-term beta-blockers, with a left ventricular ejection fraction of at least 40% and no cardiovascular events in the previous 6 months. Participants were randomised (1:1) to interrupting or continuing their β-blocker medication.
The main goal of the study was to evaluate if stopping beta-blocker therapy was not worse than continuing it, based on a combination of death, non-fatal heart attacks, non-fatal strokes, or hospitalizations for heart-related issues, measured over at least one year. Non-inferiority was defined as a difference of less than 3 percentage points between the two groups. Additionally, the study looked at changes in quality of life, using the European Quality of Life–5 Dimensions questionnaire as a measure.
In total 3,698 patients were randomised from 49 sites in France. The mean age was 64 years and 17% were female. The median time between last MI and randomisation was 2.9 years.
In the study, death rates were 4.1% in the group that stopped beta-blockers and 4.0% in the group that continued them. Heart attacks occurred in 2.5% of the interruption group and 2.4% of the continuation group. However, hospitalizations for heart-related issues were higher in the interruption group (18.9%) compared to the continuation group (16.6%).
Additionally, stopping beta-blockers led to higher systolic and diastolic blood pressure and heart rate at 6 months and throughout the study period. There was no improvement in quality of life for those who stopped the medication.
Check full updates on Medical Dialogues
Also check out -
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
📚 Explore More With Us:
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Follow us on
New research presented at ESC Congress 2024 found that stopping beta-blocker treatment after a heart attack doesn’t improve patient outcomes or quality of life compared to continuing the medication.
The open-label, non-inferiority, randomised ABYSS trial, conducted by the ACTION Group, included patients with a prior myocardial Infarction(MI) taking long-term beta-blockers, with a left ventricular ejection fraction of at least 40% and no cardiovascular events in the previous 6 months. Participants were randomised (1:1) to interrupting or continuing their β-blocker medication.
The main goal of the study was to evaluate if stopping beta-blocker therapy was not worse than continuing it, based on a combination of death, non-fatal heart attacks, non-fatal strokes, or hospitalizations for heart-related issues, measured over at least one year. Non-inferiority was defined as a difference of less than 3 percentage points between the two groups. Additionally, the study looked at changes in quality of life, using the European Quality of Life–5 Dimensions questionnaire as a measure.
In total 3,698 patients were randomised from 49 sites in France. The mean age was 64 years and 17% were female. The median time between last MI and randomisation was 2.9 years.
In the study, death rates were 4.1% in the group that stopped beta-blockers and 4.0% in the group that continued them. Heart attacks occurred in 2.5% of the interruption group and 2.4% of the continuation group. However, hospitalizations for heart-related issues were higher in the interruption group (18.9%) compared to the continuation group (16.6%).
Additionally, stopping beta-blockers led to higher systolic and diastolic blood pressure and heart rate at 6 months and throughout the study period. There was no improvement in quality of life for those who stopped the medication.
Check full updates on Medical Dialogues
Also check out -
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
📚 Explore More With Us:
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Follow us on
0:02:26
0:01:19
0:02:51
0:15:34
0:02:38
0:14:26
0:06:15
0:08:30
0:00:38
0:04:02
0:04:21
0:00:31
0:20:59
0:01:43
0:08:46
0:00:28
0:19:43
0:02:51
0:02:51
0:02:02
0:03:03
0:01:52
0:03:28
0:13:22